...
首页> 外文期刊>Internal medicine. >Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization Be Evaluated at 60 or 120 Seconds?
【24h】

Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization Be Evaluated at 60 or 120 Seconds?

机译:是否应该在60或120秒时评估选择性胰岛素促分泌剂注射试验对胰岛素瘤的定位?

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective The selective arterial secretagogue injection (SASI) test is considered indispensable for the accurate localization of insulinoma. However, the optimum timing of the post-injection evaluation is controversial, as some studies recommend 60 seconds [SASI (60 seconds)] while others support 120 seconds [SASI (120 seconds)]. The aim of this study was to determine the optimum timing for the SASI test evaluation for insulinoma localization. Methods Thirteen patients with surgically proven insulinoma were studied retrospectively. For the SASI test, immunoreactive insulin (IRI) was determined at baseline and at 30, 60, 90, and 120 seconds after calcium gluconate injection. A two-fold or greater increase in IRI over the baseline value was considered positive. The localization abilities of SASI (60 seconds) and SASI (120 seconds) were then compared. Results In 13 patients, a secretagogue was injected into 40 arteries supplying the pancreas. In the SASI (60 seconds) and SASI (120 seconds), the respective findings were as follows: positive predictive value, 72.2% and 68.2%; false positive rate, 25.0% and 35.0%; and rate of positivity in the head and body/tail, 38.5% and 46.2%. When the artery with the largest change was taken as the dominant artery, the localization detection sensitivity was 76.9% for SASI (60 seconds) and 92.3% for SASI (120 seconds). The sensitivity of morphological imaging techniques for localization ranged from 61.5-91.7%. Conclusion Compared with SASI (60 seconds) or morphological imaging, the insulinoma localization ability of SASI (120 seconds) was superior. Given these findings, we believe that the IRI level should be measured at 120 seconds in the SASI test.
机译:目的选择性动脉促分泌剂注射(SASI)测试被认为是胰岛素瘤准确定位必不可少的。但是,注射后评估的最佳时机是有争议的,因为一些研究建议60秒[SASI(60秒)],而另一些研究则支持120秒[SASI(120秒)]。这项研究的目的是确定用于胰岛素瘤定位的SASI测试评估的最佳时机。方法回顾性分析13例经手术证实的胰岛素瘤患者。对于SASI测试,在注射葡萄糖酸钙后的基线以及30、60、90和120秒时测定免疫反应性胰岛素(IRI)。 IRI比基线值增加两倍或更多被认为是阳性。然后比较了SASI(60秒)和SASI(120秒)的定位能力。结果13例患者中,促胰液被注入40个供应胰腺的动脉中。在SASI(60秒)和SASI(120秒)中,各自的发现如下:阳性预测值,72.2%和68.2%;假阳性率分别为25.0%和35.0%;头部和身体/尾巴的阳性率分别为38.5%和46.2%。将变化最大的动脉作为优势动脉时,SASI(60秒)的定位检测灵敏度为76.9%,SASI(120秒)的定位检测灵敏度为92.3%。形态学成像技术对定位的敏感性为61.5-91.7%。结论与SASI(60秒)或形态学检查相比,SASI(120秒)的胰岛素瘤定位能力更好。根据这些发现,我们认为应该在SASI测试中在120秒时测量IRI水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号